Your browser doesn't support javascript.
loading
Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally, David R; Loewenstein, Anat; Arnold, Jennifer J; Yang, Yit C; Gedif, Kinfemichael; Best, Catherine; Patel, Hersh; Tadayoni, Ramin; Heier, Jeffrey S.
Affiliation
  • Lally DR; New England Retina Consultants, Springfield, MA, USA. david.lally@neretina.com.
  • Loewenstein A; Department of Surgery, University of Massachusetts Medical School-Baystate, Springfield, MA, USA. david.lally@neretina.com.
  • Arnold JJ; Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Yang YC; Marsden Eye Specialists, Parramatta, NSW, Australia.
  • Gedif K; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
  • Best C; Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA.
  • Patel H; Novartis Pharma AG, Basel, Switzerland.
  • Tadayoni R; Novartis Pharmaceuticals Corporation, East Hannover, NJ, USA.
  • Heier JS; IVERIC bio, Inc., New York, NY, USA.
Eye (Lond) ; 37(6): 1242-1248, 2023 04.
Article in En | MEDLINE | ID: mdl-35597816
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Retinal Vasculitis / Hawks / Wet Macular Degeneration Limits: Animals / Humans Language: En Journal: Eye (Lond) Journal subject: OFTALMOLOGIA Year: 2023 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Retinal Vasculitis / Hawks / Wet Macular Degeneration Limits: Animals / Humans Language: En Journal: Eye (Lond) Journal subject: OFTALMOLOGIA Year: 2023 Type: Article Affiliation country: United States